ReviewMolecular neurobiology2025
Brain-Derived Neurotrophic Factor Trafficking via the Regulated Secretory Pathway: Mechanisms and Disease Implications.
Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gut-Brain-Skin Axis: From Mechanistic Insights to Translational Applications in Neurocosmetics.Dermatology and therapy · 2026Review
- Structured Light Music for Stress Adaptation: The BDNF/TrkB Signaling Axis Mediating Neuroplasticity and HPA Axis Regulation.Brain sciences · 2026Review
- Advances in Clostridial Neurotoxins: Passage of the Intestinal Barrier and Targeting of Specific Neuronal Cells.Toxins · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain-derived neurotrophic factor (BDNF) plays an essential role in neuronal development and synaptic plasticity. BDNF's role in neuronal function is dependent on its trafficking through the regulated secretory pathway (RSP). This review provides a synthesis of the molecular mechanisms underlying anterograde BDNF trafficking with an emphasis on the role of sorting receptors (e.g., sortilin, carboxypeptidase E), motor proteins (e.g., kinesin), and scaffolding proteins (e.g., huntingtin, huntingtin-associated protein-1 1, dynactin). Despite major advances in elucidating the molecular players involved in BDNF trafficking, many regulators, such as adaptor proteins, ADP ribosylation factor GTPases, granins, and myosins, remain poorly characterized. However, given that impaired BDNF trafficking has been implicated in multiple neurodegenerative, neuropsychiatric, and neurodevelopmental disorders, understanding the trafficking of BDNF in full not only uncovers fundamental aspects of BDNF function but also reveals potential therapeutic targets for neurological disorders that are associated with impaired BDNF trafficking. This review summarizes current knowledge of anterograde BDNF trafficking from biosynthesis to regulated exocytosis and highlights its importance for neuronal function and human disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.